Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLCFan Zhang, Jie He, Wei Guo et al.|Journal of Thoracic Oncology|2022Cited by 74
Effect of low-ratio n-6/n-3 PUFA on blood glucose: a meta-analysisNa Li, Tongcheng Xu, Hao Yue et al.|Food & Function|2019Cited by 57
<scp>TIGIT</scp>/<scp>CD47</scp> dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinomaYue Peng, Shugeng Gao, Fenglong Bie et al.|Thoracic Cancer|2022Cited by 12
Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancerBolun Zhou, Shugeng Gao, Fan Zhang et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 8
Circulating tumor DNA as markers of dynamic recurrence risk and adjuvant chemotherapy benefit in resected non-small cell lung cancer.Wei Guo, Shugeng Gao, Fan Zhang et al.|Journal of Clinical Oncology|2021Cited by 2